Introduction: Approximately 50% of recurrences after standard-dose chemoradiation for locally advanced esophageal cancer occur within the gross tumor volume (GTV). In this prospective phase I/II clinical trial, we explored the use of a simultaneous integrated boost (SIB) dose to the GTV.
Methods: Forty-four patients with unresectable esophageal cancer received chemoradiation with an SIB of 58.8 to 63 Gy to the GTV and 50. 4 Gy to the planning target volume, all in 28 fractions, with 5 weeks of concurrent docetaxel and fluorouracil or capecitabine. The end points were maximum tolerated dose, time to local failure, and clinical response.
Results: Excluding those with less than 6 months of followup, 38 patients were evaluated at the time of analysis. The median age was 65 years (range 37-84). Most patients (71%) were men; 84% had T3 disease, 37% had N1 disease, 26% had N2 disease, 13% had M1 disease, and 50% had adenocarcinoma. The maximum tolerated SIB dose was 63 Gy. None experienced Common Terminology Criteria for Adverse Events grade 4 or 5 toxicity. At a median follow-up time of 13.3 months (range 1.2-36.2), 11 (29%) had local failure (median time to local failure 2.5 months [range 1.5-23.9]). A comparison with 97 similar patients who received 50. 4 Gy without an SIB showed that the SIB reduced the local failure rate for patients with node-positive disease (13% versus 56%, p ¼ 0.04), adenocarcinoma (26% versus 59%, p ¼ 0.02), or stage III-IV disease (29% versus 55%, p ¼ 0.04).
Conclusions: SIB intensity-modulated radiation therapy to gross primary disease may improve local control for patients with unresectable locally advanced esophageal cancer, especially those with adenocarcinoma.
Introduction
The currently preferred treatment for locally advanced esophageal cancer is trimodality therapy consisting of concurrent chemoradation followed by surgery, 1, 2 an approach that produces 5-year overall survival (OS) rates ranging from 35% to 50%. 1, 3, 4 In this approach, radiation is given with the intent of sterilizing microscopic nodal disease and improving the likelihood of an R0 (complete) resection. The survival benefit from neoadjuvant chemoradiation followed by surgery relative to surgery alone was demonstrated in the prospective CROSS trial. 1, 3 However, many patients are not considered candidates for surgery owing to the extent of disease or the presence of comorbid conditions. If chemoradiation is being used as definitive therapy for patients who cannot tolerate surgery, should the radiation dose be increased from a preoperative dose (intended to address microscopic disease) to a dose more commonly used to control gross disease?
Previous attempts to address this question have included our own retrospective analysis of failure patterns among patients with inoperable esophageal cancer after 50.4 Gy 5 and the randomized phase III Intergroup-0123 study (Radiation Therapy Oncology Group 94-05). Our retrospective analysis showed that 49% of patients experienced local recurrence, and nearly all of those recurrences appeared within the gross tumor volume (GTV), suggesting that 50.4 Gy is not sufficient to treat disease in patients who will not receive an operation. The Intergroup-123 trial, in which patients undergoing definitive chemoradiation for locally advanced esophageal cancer were randomly assigned to receive either the conventional 50.4-Gy dose or a higher 64.8-Gy dose, 2 showed that the higher radiation dose did not confer benefits in local control or OS. However, the radiation in that study was delivered as traditional two-dimensional (2D) therapy, with a cone-down boost to the tumor of 14.4 Gy in the high-dose group. 2 In the modern era, 2D radiation therapy has given way to three-dimensional conformal radiation therapy (CRT) and subsequently to intensity-modulated radiation therapy (IMRT), which offers further improvements in conformality. We previously confirmed in a treatmentplanning comparison that dose distributions could be improved by using IMRT rather than 2D CRT, with a dose of 50.4 Gy to the GTV with or without a simultaneous integrated boost (SIB) to a total dose of 64.8 Gy. In that study, the lung V20 and mean heart dose were lower in the high-dose SIB-IMRT plan than in the 2D CRT 50.4-Gy plan despite the higher dose to the tumor. 6 Our subsequent dosimetric comparison of IMRT with intensity-modulated proton therapy (IMPT) revealed that three-field IMPT could spare heart and lungs to an even greater extent than could IMRT. 7 Although the dosimetric evidence seems convincing, we are giving a boost dose to a tumor that resides within a critical structure (the esophagus), and this requires clinical validation to ensure that treatment-related toxicity is not enhanced. We thus undertook a phase I/II trial (NCT01102088) to explore the safety and feasibility of IMRT with an SIB, given concurrently with chemotherapy, for inoperable or high-risk esophageal cancer. Preliminary findings from that study are reported here, as are findings from exploratory analyses of late toxicity, OS, selective use of surgery after chemoradiation, and ad hoc comparisons of these findings with those of a historical control group of patients who received conventional-dose chemoradiation (to 50.4 Gy) without an SIB. Additional outcome measures are reported in this study from what was initially proposed in this clinical trial, with the goal of further understanding the radiobiology of esophageal cancer and initiating further discussion about the feasibility of using SIB-IMRT along with a selective approach for esophageal cancer.
Patients and Methods

Eligibility Criteria
From June 2010 through December 2014, 44 patients with locally advanced esophageal cancer were enrolled in an institutional review board-approved phase I/II study at The University of Texas M. D. Anderson Cancer Center. No more than 10 cm of tumor could be treated with a boost dose, with a maximum 2-cm penetration into the stomach. Patients with stage IV disease receiving consolidation chemoradiation were eligible. Each patient was evaluated by a multidisciplinary tumor board that considered disease stage, tumor location, age, and the presence of comorbid conditions and deemed participants either as having inoperable disease or being a high-risk surgical candidate. For the purpose of comparison, we further identified a historical control group of 97 patients with esophageal cancer who had received definitive chemoradiation (50.4 Gy in 28 fractions) with IMRT, without an SIB, at M. D. Anderson Cancer Center from January 2002 to January 2009. We accessed these patients from an accessible partial data set of 239 patients. 5 Only patients with complete follow-up imaging along with biopsies as mentioned later were included. Patients with less than 6 months of follow-up were excluded unless their disease recurred or was the cause of death.
Diagnostic and Pretreatment Evaluation
Disease was staged in all cases according to the seventh (2010) edition of the American Joint Committee on Cancer (AJCC) staging system and included information obtained from positron emission tomography/ computed tomography (PET/CT), endoscopic ultrasonography, or esophagogastroduodenoscopy (EGD).
Chemotherapy and Radiation Treatment Planning and Delivery
All patients received docetaxel (200 mg/m 2 ) and fluorouracil (300 mg/m 2 ) or capecitabine chemotherapy for 5 weeks concurrently with radiotherapy. The internal GTV (iGTV) was contoured by using data from PET/CT fusion scans. PET-avid lymph nodes were also included within the iGTV. The boost dose to the GTV was up to 63 Gy in 28 fractions and consisted of the iGTV with a 3-mm expansion in all directions. The clinical target volume (CTV) was created by expanding the iGTV by 3 cm superiorly, 3 cm inferiorly and 1 cm radially. Positive lymph nodes within the iGTV were uniformly expanded by 0.5 cm as part of the CTV. For cancers located within the gastroesophageal junction, a 3-cm expansion into the gastric mucosa was allowed and then manually refined on the basis of the patient's anatomy at the discretion of the treating radiation oncologist. The planning target volume (PTV) was generated by using a uniform 0.5-cm expansion around the CTV.
For the phase I evaluation of dose-related toxicity, two dose levels were tested. The first three patients were given 58.8 Gy in 28 fractions (2.1 Gy per fraction) to the GTV, with a dose to the PTV of 50.4 Gy. To asses for the maximum tolerated dose (MTD), these patients were seen weekly during radiation treatment and 1 month after its completion. Because these patients did not display grade 4 or 5 esophagitis during the evaluation period, the dose to the GTV was increased to 63 Gy (28 fractions at 2.25 Gy per fraction), with the same 50.4 Gy to the PTV for future patients. Both IMRT and IMPT were allowed depending on physician preference. Nine patients in this study received an operation after definitive chemoradiation for suspicious residual disease noted on either imaging (EGD or PET-CT) or posttreatment biopsy.
Toxicity Evaluation
Toxicity was classified according to the Common Terminology Criteria for Adverse Events, version 3.0. In this system, grade 1 esophagitis was asymptomatic, with only clinical or diagnostic findings; grade 2 was symptomatic, involving altered eating and/or swallowing, with oral supplements indicated but intervention not indicated; grade 3 was characterized by severely altered eating and/or swallowing, with intravenous fluids, tube feeding, or total parenteral nutrition indicated; grade 4 involved life-threatening consequences; and grade 5 was esophagitis resulting in death. Toxicity was monitored monthly during treatment and for up to 12 months afterward.
Follow-up and Disease Recurrence
Each clinic visit included an interval history and physical examination, with serum laboratory analyses and imaging if indicated. A clinical complete response (CR) was defined as the disappearance of all disease on imaging (PET or CT), as well as having no evidence of disease on endoscopic ultrasonography-guided biopsy, which was done routinely at 1 to 3 months after treatment (or for patients who received an operation after the chemoradiation, as no evidence of disease in the surgical specimen). Radiographic CR was absence of disease on follow-up imaging alone. Recurrences were classified as local/in-field (within the GTV, CTV, or PTV), or distant/ out-of-field on the basis of posttreatment images. Patients who were found to have residual disease after surgery were categorized as having GTV failure.
Statistical Analyses
The primary outcome measure for this phase I/II study was gastrointestinal toxicity of the SIB, defined by Common Terminology Criteria for Adverse Events criteria after treatment initiation. The secondary outcome measures were time to local failure, which was assessed by PET or CT and the local failure rate at 1 year, and the rates of clinical response (originally termed pathologic) at 2 months after radiation therapy, which was defined as no evidence of gross or microscopic tumor in the biopsy specimen from EGD or the surgical specimen on light microscopy (immunohistochemical staining was not used). Partial pathologic response was defined as tumor shrinkage relative to findings from the original EGD.
Data were analyzed with Stata/MP 14.0 software (StataCorp, College Station, TX). Fisher's exact tests were used to assess measures of association in frequency tables. Local failure-free survival proportions were estimated with the Kaplan-Meier method, and log-rank tests were used to assess differences across groups. The equality of group medians was assessed with nonparametric tests for equality, and p values less than 0.05 were considered to indicate statistical significance. Statistical tests were based on a two-sided significance level. A Cox proportional hazard model was used for univariate analysis to assess the possible effect of patient, tumor, and other variables on the end points (toxicity and local disease control). Multivariate analysis was not done because of limited patient numbers. Estimated hazards are reported, and the Wald test was used to assess the role of covariates in the model.
Results
Patient Characteristics
A total of 44 patients were enrolled in this study; six were excluded for having 6 months or less of follow-up time (none of whom had recurrent disease or died during that time), leaving 38 eligible for analysis. Characteristics of these patients are shown in Table 1 . The median patient age was 65 years. Most patients (71%) were male and most had T3 disease (84%); 37% had N1 disease, 26% had N2 disease, 13% had M1 disease, and 42% had moderately differentiated tumors. The median tumor length was 5 cm (range 2-11 cm). Half of the tumors were adenocarcinomas. The median follow-up time at the time of this analysis was 13.3 months (range 1
MTD and Toxicity
The MTD for this study was determined to be 63 Gy, as none of the first three patients given 58.8 Gy experienced grade 3 acute esophagitis.
No patient experienced grade 4 or 5 acute treatment-related toxicity. Esophagitis was the most common adverse event (92%, any grade). One or more of the following conditions developed in most patients: grade 1 or 2 dysphagia (63%), weight loss (79%), fatigue (82%), nausea (66%), and anorexia (60%). Excluding patients who had baseline adverse events before chemoradiation (eight for dysphagia and one for anorexia), grade 3 toxic effects during treatment included esophagitis (three patients), dysphagia (three patients), and anorexia (two patients).
In terms of long-term toxicity, stricture was seen in six patients (22%); those patients required a median 1.5 dilations. Patients with adenocarcinoma experienced lower rates of stricture (8%) than did those with squamous cell carcinoma (SCC) (36%). Multivariate logistic regression analysis suggested that the SCC histologic type has been associated with the development of stricture (OR ¼ 6.74 versus adenocarcinoma, p ¼ 0.04). 
Patterns of First Failure
At the most recent follow-up, 11 patients (29%) had experienced local failure alone, distant failure alone had developed in 17 (45%), five (13%) had both distant and local recurrence, and 15 (39%) had no evidence of disease. In the comparison group, 54% had local failure, 29% had distant failure, and 27% had no evidence of disease (Fig. 1) . Because this trial included five patients with M1 disease, we also assessed OS for patients with localized (M0) disease (33 patients) separately to facilitate comparisons with other trials (e.g., CROSS). Patients with M0 adenocarcinoma who received the 63-Gy dose had OS rates of 94% at 1 year, 67% at 2 years, and 67% at 3 years. The Kaplan-Meier survival estimate for OS time was not reached.
Predictors of Local Disease Control
Outcomes for Surgical Patients
Nine of the 38 evaluable patients underwent esophagectomy after chemoradiation, including five who had evidence of malignancy on imaging (all within the GTV). Median follow-up time for these patients was 12.8 months. All patients experienced distant (out-of-field) recurrence. The five local failures all occurred within the first year. No patient experienced intraoperative complications, but eight patients experienced at least one of the following postoperative complications: wound infection, acute respiratory distress syndrome, gastric outlet obstruction, small bowel obstruction, aspiration pneumonia, non-aspiration-related pneumonia, and atrial fibrillation. None of these nine patients died within the first 90 days after surgery.
Local Failure Comparisons
Next, we compared local failure rates between groups, and potential predictors of local failure, with Fisher's exact tests (Table 2 ). Local failure rates, at any time (29% versus 54%, p ¼ 0.01), within the first (26% versus 31%, p ¼ 0.38), and within the third (29% versus 49%, p ¼ 0.04) year after treatment, were lower for patients who received an SIB ( Table 2 ). Receipt of a boost dose was also associated with lower local failure rates in patients with node-positive disease (13% versus 56%, p ¼ 0.04), adenocarcinoma (26% versus 59%, p ¼ 0.02), and AJCC stage III-IV disease (29% versus 55% stage I-II, p ¼ 0.04). More patients in the comparison group (51%) than in the SIB-IMRT group (29%) (p ¼ 0.03) had their first failure within the GTV. Posttreatment SUV was more likely to be less than 4 in the SIB-IMRT group than in the conventional-dose group (48% versus 38%, p ¼ 0.50), and posttreatment SUV was lower in the SIB-IMRT group than in the conventionaldose group (median SUV 3.8 versus 5.3) (p ¼ 0.01). SIB-IMRT was also associated with a greater absolute Figure 1 . First sites of failure among patients with esophageal cancer who received a simultaneous integrated boost (dose escalation) to 63 Gy to the gross tumor volume by intensity-modulated radiation therapy and a comparison group who received intensity-modulated radiation therapy to 50.4 Gy without a boost dose. NED, no evidence of disease. reduction in PET SUV after treatment (median -9.1 versus -5.3), although this apparent difference was not statistically significant (p ¼ 0.10).
Next, we used Kaplan-Meier analysis to evaluate the proportions of local failures over a 3-year interval. When all patients were considered by treatment group, the proportions of patients without failure in the SIB-IMRT group were 69.9% at 1 year, 59.9% at 2 years, and 59.4% at 3 years; the corresponding rates were no different in the comparison group, at 66.3%, 45.2%, and 30.8% (p ¼ 0.31) (Fig. 2A) . We next stratified the patients by tumor histologic type and found that the local failure-free proportions remained constant over time for patients with adenocarcinoma after SIB-IMRT (70.7% at 1 year, 2 years, and 3 years) and seemed to be better for patients with adenocarcinoma who received standard therapy (66.7% at 1 year, 41.9% at 2 years, and 29.6% at 3 years), but this apparent difference was also not statistically significant (p ¼ 0.29) (Fig. 2B ). Local control rates were roughly the same for patients with SCC in the 63-Gy group (69.3% at 1 year versus 52.0% at 2 years) and those given 50.4 Gy without the SIB (68.9% at 1 year versus 59.1% at 2 years) (p ¼ 0.90) (Fig. 2C) . We also analyzed local control over time for patients with adenocarcinoma who had achieved pathologic CR and found consistently high local control rates in the SIB-IMRT group (83.6% at 1, 2, and 3 years) compared with in patients with adenocarcinoma who achieved clinical CR after conventional-dose treatment (81.4% at 1 year, 59.9% at 2 years, and 44.4% at 3 years), although these apparent differences were also not statistically significant (p ¼ 0.22) (Fig. 2D ).
Discussion
Our phase I/II trial has demonstrated the feasibility of selectively escalating the dose to the GTV by using a high-dose SIB-IMRT technique, with 63 Gy to the GTV, and concurrent chemotherapy. The rate of acute esophagitis was similar to that in the historic controls, as was the rate of long-term toxicity of stricture. Interestingly, the greatest benefit in terms of improved local control appears to be in the patients with adenocarcinoma, a histologic type that is becoming more prevalent in the United States. This provides a unique insight compared with the prior dose escalation trials out of Asia, which are predominantly for the SCC histologic type, a subgroup in which we saw little benefit to dose escalation. The CROSS trial compared surgery with or without chemoradiotherapy (to a dose of 41.4 Gy) for patients with esophageal cancer. 3 Although our patients were not candidates for trimodality therapy, our OS rates were similar. The 3-year OS rate for patients with nonmetastatic adenocarcinoma in our study was 67% versus an estimated 60% in the trimodality arm from the CROSS trial. Moreover, in the CROSS trial, 10 patients (6%) died within the first 30 days after surgery; in our study, no patient experienced grade 4 or 5 toxicity. Of the nine patients in our trial who underwent surgery, only five (56%) had evidence of residual disease at surgery. Given that 46% of our patients with M0 disease did not experience relapse, this raises the question as to whether immediate surgery should be mandated, especially if residual disease is not found on posttreatment endoscopy.
The Radiation Therapy Oncology Group 0246 study attempted to answer this question by adopting a selective surgical approach, operating on only those patients who did not achieve clinical CR on biopsy after chemoradiation (41% of patients in that study). The trial resulted in a 1-year OS rate of 71% for all patients. 8 In the context of a selective surgical approach, one might propose using a higher radiation dose to improve the local control rate, as the clinical CR rate in our trial was 71%.
This study is not the first prospective evaluation of using high-dose radiation for esophageal tumors. Yu et al. examined the safety of 70 Gy in 25 fractions to the GTV using IMRT in 25 patients with esophageal SCC. 9 However, the mean follow-up time in this study was shorter than in the trial presented (8.9 versus 18 months). Nonetheless, median OS rate and local control rates at 1 year were similar (69% and 77%). However, stricture developed in fewer patients (8%). The reason for this difference is unclear but may reflect minor differences in the chemotherapy regimens used. Another group examined 60 patients with SCC treated with IMRT to 66 Gy in 33 fractions. 10 They noted a higher 1-year local control rate (87.6%) but similar OS rate (72.7%), with a median follow-up time of 24 months. The discrepancy in local control could be from the larger number of patients with SCC and the longer follow-up time. Nonetheless, neither trial enrolled patients with adenocarcinoma. Interestingly, our trial suggests that patients with adenocarcinoma not only had the greatest benefit from the higher-dose regimen but also had a lower stricture rate. This is particularly important, as adenocarcinoma is the predominant form of esophageal cancer in the United States. Further, patients with adenocarcinoma who achieved clinical CR had better local control after the SIB-IMRT regimen as compared with a historical control group given conventional-dose therapy without the boost, implying that higher-dose radiation could increase the durability of clinical CR. Zeng and et al. recently published a retrospective study of 17 patients with resectable nonmetastatic esophageal adenocarcinoma who received neoadjuvant concurrent chemoradiation with 56 Gy to the GTV followed by surgery. They reported a local recurrence rate of 11% at 22 months compared with the 29% at 3 years in this study. 11 However, the patients selected in Zeng et al. study all had M0 disease, whereas most (71%) presented with N0 disease in contrast to the patients presented in this trial (13% with M1 disease and 63% with N1/N2 disease), making comparison difficult. Further follow-up will determine the importance of SIB-IMRT in local control. Finally, SIB-IMRT resulted in comparable OS rates for patients with adenocarcinoma in our study and in the trimodality subset from the CROSS trial.
One of the major weaknesses of this trial is the small number of evaluable patients (n ¼ 38) and the short follow-up time (18 months for those alive at the time of this analysis). These shortcomings are reflected in the fact that none of the patients who received SIB-IMRT displayed a statistically significant local failure free survival benefit (Fig. 2) despite histologic stratification. As a result, any multivariate Cox regression analysis would not be reliable.
In conclusion, our findings demonstrate the safety and feasibility of SIB-IMRT for esophageal cancer, with toxicity rates similar to those after standard-dose radiation. We conclude that use of an SIB with IMRT or IMPT may improve local control of esophageal cancer, particularly adenocarcinoma. Prospective randomized trials to directly compare standard-dose radiation to dose escalation treatments are needed.
